Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease

开发 PU.1 抑制调节剂作为阿尔茨海默病的新疗法

基本信息

  • 批准号:
    10159826
  • 负责人:
  • 金额:
    $ 159.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-05-15 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Alzheimer's disease (AD) is a fatal neurodegenerative disease with a global prevalence close to 50 million people, which is expected to double by 2040. Finding an effective treatment for AD has proven difficult, as evidenced by numerous high profile Phase 3 clinical trial failures, most of which directly target the reduction of ß-amyloid. Thus, it is becoming increasingly urgent to develop new pharmacological strategies to combat AD. Drugs are twice as likely to successfully negotiate the drug development pipeline and obtain FDA approval when their targets are supported from human genetic studies of disease. Human genetic studies have revealed a critical role for microglia involvement in Alzheimer’s disease progression, and it has recently been discovered that the transcription factor PU.1 is a driver of the pro-neurodegenerative phenotype adopted by microglia during aging and disease. This proposal therefore aims to develop novel, newly-discovered PU.1 Inhibitory Modulators (PIMs) for preclinical development, with the long term goal of clinically testing the hypothesis that reducing PU.1 activity in microglia will safely delay the age of AD onset (AAO) in at-risk populations. The studies in this proposal leverage the interdisciplinary structure of the Neurodegeneration Consortium, a unique collaboration between basic science researchers and industry drug development veterans operating under a collaborative agreement to push forward novel therapeutics aimed at treating Alzheimer’s diseaes and other neurodegenerative diseases. Under Specific Aim 1, the in vivo safety and efficacy of PIMs will be determined in mouse models of AD. Under Specific Aim 2, parallel target engagement studies will be performed to identify the target of PIMs, and the identified targets will be used to develop assays to determine the efficacy of PIMs in AD and in ex vivo models. Under Specific Aim 3, selected PIMs will be optimized using PK/PD and ADMET screening to develop lead tool compounds into candidate compounds suitable for future Phase I studies. The combined biology, chemistry, and pharmacology expertise in the Neurodegeneration Consortium, spanning The University of Texas MD Anderson Cancer Center, the Massachussets Institute of Technology, and the Mt. Sinai School of Medicine, make this group of researchers ideally suited to execute the proposed aims.
项目总结/摘要 阿尔茨海默病(Alzheimer's disease,AD)是一种致命的神经退行性疾病,全球患病率接近5000万 预计到2040年将翻一番。找到有效的治疗AD已被证明是困难的, 许多引人注目的3期临床试验失败证明了这一点,其中大部分直接针对减少 淀粉样蛋白。因此,开发新的药物策略来对抗AD变得越来越迫切。 药物成功谈判药物开发管道并获得FDA批准的可能性是其他药物的两倍, 它们的目标得到了人类疾病基因研究的支持。人类基因研究显示, 小胶质细胞参与阿尔茨海默病进展的关键作用,最近发现 转录因子PU.1是小神经胶质细胞在发育过程中采用的促神经退行性表型的驱动因子。 衰老和疾病因此,该提案旨在开发新发现的新型PU.1抑制性调节剂 (PIM)用于临床前开发,长期目标是在临床上测试减少PU的假设。 在高危人群中,小胶质细胞的活性将安全地延迟AD发病年龄(AAO)。 本提案中的研究利用了神经退行性疾病联盟(Neurodegeneration Consortium)的跨学科结构,该联盟是一个 基础科学研究人员和行业药物开发资深人士之间的独特合作 根据一项合作协议,推动旨在治疗阿尔茨海默病的新疗法, 其他神经退行性疾病。根据具体目标1,将评估PIM的体内安全性和有效性 在AD的小鼠模型中测定。在特定目标2下,将进行平行的目标参与研究 确定PIM的靶点,并将确定的靶点用于开发测定疗效的试验 在AD和离体模型中的PIM。在具体目标3下,将使用PK/PD优化选定的PIM, ADMET筛选,将先导工具化合物开发为适合未来I期研究的候选化合物。 神经退行性疾病联盟的生物学、化学和药理学专业知识, 德克萨斯大学MD安德森癌症中心、马萨诸塞州理工学院和麻省理工学院。 西奈医学院,使这组研究人员非常适合执行提出的目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALISON M GOATE其他文献

ALISON M GOATE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALISON M GOATE', 18)}}的其他基金

Neuroprotective signaling and transcriptional pathways in microglia associated with Alzheimer's disease
与阿尔茨海默病相关的小胶质细胞的神经保护信号传导和转录途径
  • 批准号:
    10552538
  • 财政年份:
    2022
  • 资助金额:
    $ 159.55万
  • 项目类别:
2022 Neurobiology of Brain Disorders GRC and GRS
2022年脑部疾病神经生物学GRC和GRS
  • 批准号:
    10468475
  • 财政年份:
    2022
  • 资助金额:
    $ 159.55万
  • 项目类别:
Neuroprotective signaling and transcriptional pathways in microglia associated with Alzheimer's disease
与阿尔茨海默病相关的小胶质细胞的神经保护信号传导和转录途径
  • 批准号:
    10301271
  • 财政年份:
    2022
  • 资助金额:
    $ 159.55万
  • 项目类别:
Genetic modifiers of APOE-related risk for AD
APOE 相关 AD 风险的基因修饰
  • 批准号:
    10667481
  • 财政年份:
    2021
  • 资助金额:
    $ 159.55万
  • 项目类别:
Project 1: Determination of molecular differences caused by tauopathy-associated H1 and H2 haplotypes
项目 1:确定 tau 蛋白病相关 H1 和 H2 单倍型引起的分子差异
  • 批准号:
    10295517
  • 财政年份:
    2021
  • 资助金额:
    $ 159.55万
  • 项目类别:
Biology and pathobiology of apoE in aging and Alzheimer's disease
apoE 在衰老和阿尔茨海默病中的生物学和病理学
  • 批准号:
    10407934
  • 财政年份:
    2021
  • 资助金额:
    $ 159.55万
  • 项目类别:
Core A: Administrative
核心A:行政
  • 批准号:
    10295513
  • 财政年份:
    2021
  • 资助金额:
    $ 159.55万
  • 项目类别:
Biology and pathobiology of apoE in aging and Alzheimer's disease
apoE 在衰老和阿尔茨海默病中的生物学和病理学
  • 批准号:
    10667435
  • 财政年份:
    2021
  • 资助金额:
    $ 159.55万
  • 项目类别:
Genetic modifiers of APOE-related risk for AD
APOE 相关 AD 风险的基因修饰
  • 批准号:
    10407948
  • 财政年份:
    2021
  • 资助金额:
    $ 159.55万
  • 项目类别:
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease
开发 PU.1 抑制调节剂作为阿尔茨海默病的新疗法
  • 批准号:
    10435506
  • 财政年份:
    2020
  • 资助金额:
    $ 159.55万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 159.55万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 159.55万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 159.55万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 159.55万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 159.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 159.55万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 159.55万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 159.55万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 159.55万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 159.55万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了